secwatch.observer — SEC 8-K summary
======================================

Issuer:     NEKTAR THERAPEUTICS (NKTR)
CIK:        0000906709
Form:       8-K
Filed at:   2025-06-24T23:59:59+00:00
Accession:  0001213900-25-056909
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nektar’s rezpegaldesleukin meets primary & key secondary endpoints in Phase 2b atopic dermatitis trial
--------------------------------------------------------------------------------

- REZOLVE-AD met primary endpoint: mean EASI improvement from baseline at week 16 for all three rezpegaldesleukin dose arms vs placebo (p<0.001).
- EASI-75 achieved by 42-46% of rezpegaldesleukin patients vs 17% placebo; high dose also significant on EASI-90 (25% vs 9%).
- Itch NRS (≥4-point reduction) 42% high dose, 35% middle dose vs 16% placebo; vIGA-AD 0/1 significant for q2w arms.
- Safety profile consistent: injection site reactions (69.7%) mostly mild/moderate; no increased conjunctivitis, oral ulcers, or infections.
- On-target Treg proliferation up to 6-fold; full 52-week data expected early 2026, alopecia areata top-line Q4 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/906709/000121390025056909/0001213900-25-056909-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/906709/000121390025056909/ea0246672-8k_nektar.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-056909

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer